ICT-107 is a multiple antigen DC-vaccine directed against six epitopes (AIM-2, MAGE1, TRP-2, gp100, HER2, and IL-13Ra2), and was tested in patients with a new diagnosis of GBM in a pilot study. This evidence concerns the gene ERBB2 and glioblastoma.